Pianta Timothy J, Peake Philip W, Pickering John W, Kelleher Michaela, Buckley Nicholas A, Endre Zoltan H
Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
Northern Clinical School, Melbourne Medical School, University of Melbourne, Epping, Vic, Australia.
Transpl Int. 2015 Dec;28(12):1392-404. doi: 10.1111/tri.12636. Epub 2015 Jul 28.
Early prediction of delayed graft function (DGF) after kidney transplantation would facilitate patient management. Cell cycle arrest and inflammation are implicated in the pathogenesis of DGF. We assessed the utility of two novel acute kidney injury (AKI) biomarkers, urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7), and five inflammatory markers to predict DGF following deceased-donor kidney transplantation. Serial urine concentrations of TIMP-2 and IGFBP7 were measured immediately after transplantation in 56 recipients along with vascular endothelial growth factor-A (VEGF-A), macrophage migration inhibitory factor (MIF), monocyte chemotactic protein-1 (MCP-1), trefoil factor 3 (TFF3) and chemokine (C-X-C) ligand 16 (CXCL16). Delayed graft function (DGF) was defined as requirement for dialysis within 7 days. Integrated discrimination improvement analysis was used to evaluate whether these biomarkers enhanced prediction of DGF independently of a validated clinical risk prediction model. DGF occurred in 22 patients (39%). At 4 h after kidney reperfusion, the area under the receiver operator characteristic curve (AUC) for VEGF-A was good (AUC > 0.80); for TIMP-2, IGFBP7 and [TIMP-2] × [IGFBP7] fair (AUCs 0.70-0.79); and for MIF, MCP-1, TFF3 and CXCL16 poor (AUC < 0.70). Only TIMP-2 and VEGF significantly enhanced the DGF prediction at 4 and 12 h. The cell cycle arrest marker urinary TIMP-2 and the inflammatory biomarker VEGF-A are potentially useful adjuncts to clinical data for early prediction of DGF.
肾移植后延迟移植肾功能(DGF)的早期预测将有助于患者管理。细胞周期停滞和炎症与DGF的发病机制有关。我们评估了两种新型急性肾损伤(AKI)生物标志物——尿金属蛋白酶组织抑制剂-2(TIMP-2)和胰岛素样生长因子结合蛋白7(IGFBP7),以及五种炎症标志物预测死亡供者肾移植后DGF的效用。在56例受者移植后立即测量TIMP-2和IGFBP7的系列尿浓度,同时检测血管内皮生长因子-A(VEGF-A)、巨噬细胞迁移抑制因子(MIF)、单核细胞趋化蛋白-1(MCP-1)、三叶因子3(TFF3)和趋化因子(C-X-C)配体16(CXCL16)。延迟移植肾功能(DGF)定义为7天内需要透析。采用综合鉴别改善分析来评估这些生物标志物是否独立于经过验证的临床风险预测模型增强对DGF的预测。22例患者(39%)发生了DGF。在肾再灌注后4小时,VEGF-A的受试者操作特征曲线下面积(AUC)良好(AUC>0.80);TIMP-2、IGFBP7和[TIMP-2]×[IGFBP7]的AUC中等(AUC为0.70-0.79);MIF、MCP-1、TFF3和CXCL16的AUC较差(AUC<0.70)。仅TIMP-2和VEGF在4小时和12小时显著增强了对DGF 的预测。细胞周期停滞标志物尿TIMP-2和炎症生物标志物VEGF-A可能是早期预测DGF的临床数据的有用辅助指标。